... a dynamic, daily updated,
   fully relational, user-friendly,
   comprehensive resource in global 
   drug development in oncology
Subscriber Login
User ID:  

Follow oncology_drugs on Twitter


A free glossary of oncology-related terms and resource organizations.

About nm|OK

Why use a resource like nm|OK?
Unlike reports that are 'dead on arrival' nm|OK is a constantly updated comprehensive report on every aspect of oncology drug development.  click

Drugs profiled in nm|OK

nm|OK profiles over 4,310 drugs/in vivo imaging agents in development:

3,653 anticancer agents addressing over 100 cancer types and thousands of clinical indications. Of these, 1,695 are in active development; 821 have been or are currently being evaluated in clinical trials and 539 of these are targeted agents.

757 drugs for the management of complications of cancer and its treatment (pain, infection, mucositis, emesis, etc.)
nm|OK also profiles over 552 marketed drugs (anticancer agents=335, adjuncts=197) globally, providing trial results from monotherapy and combination therapy trials.

In vitro testing (IVT) products

nm|OK profiles over 200 companies and hundreds of products (screening tests, diagnostics, pharmacogenomics, prognostics, disease monitoring tests, theragnostics, etc.) in the in vitro testing area in oncology.

Enabling technologies/drug delivery

nm|OK describes hundreds of technology platforms used to discover, evaluate, optimize, and or deliver anticancer agents such as cytotoxics, synthetic nucleic acid sequences, small molecule drugs, monoclonal antibodies, fusion proteins, etc.

Targets in oncology

nm|OK describes over 1,000 molecular moieties that may be target candidates of anticancer strategies or used as in vitro testing markers. 

Shorthanded?  Need a cost-effective way to monitor developments in oncology. New Medicine provides numerous services:

Need an update on certain items in nm|OK?  click

Need to access certain records/saved searches on  a routine basis? click

Require more in-depth reports on certain developments in oncology? click

Would your oncology effort benefit from an in-house resource like nm|OK that allows you to combine nm|OK with secure proprietary data?  click


The headlines below refer to selected records among the hundreds updated in nm|OK within a 30-day period. A summary of the updated information, the complete records for each item on the list, and numerous other updated entries are available to subscribers upon logging in. Samples of records from each module are here.

Special reports are reviews of current developments of oncology and related drugs by indication, mechanism, delivery technology, etc. as well as personalized medicine, including biomarkers, diagnostics, theragnostics, prognostics, pharmacogenomics, disease monitoring tests, etc. Samples of special reports are here.


Vaccines 2014 Conference

New Drugs And Marketed Drugs

Company, Targets and In Vitro Tests



Special Reports and Additional News

New Drugs
(click for detailed news feed)


Talimogene laherparepvec OncoVEX GM-CSF, OncoVEXGMCSF, OncoVEXGM-CSF, Tvec


GDC-0917, CUDC-427



Niraparib MK-4827, MK4827

Vintafolide EC145, MK-8109


Nintedanib BIBF 1120


Entinostat MS-275, MS275, SNDX-275, NSC 706995

Marketed Drugs
(click for detailed news feed)






(click for detailed news feed)

Exact Sciences

Northwest Biotherapeutics

TetraLogic Pharmaceuticals

Adaptive Biotechnologies

Rosetta Genomics



Castle Biosciences

Gem Pharmaceuticals

Targets in Oncology
(click for detailed news feed)

Folate receptor 1 (FOLr1)


Vintafolide (Vynfinit) Headed for Approval in the EU for the Treatment of Patients with Folate Receptor (FOLr)-positive, Platinum-resistant Ovarian Cancer
After 12 years in development vintafolide (Vynfinit), under development by Endocyte in collaboration with Merck, and companion imaging components Folcepri (etarfolatide), and Neocepri (IV folic acid), are headed for approval in the European Union (EU) for the treatment of folate receptor (FOLr)-positive platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin (PLD). Vintafolide, a conjugate of folic acid (B9) and the potent microtubule inhibiting agent, desacetylvinblastine hydrazide (DAVLBH), targets tumor cells expressing FOLr. Etarfolatide is a peptide derivative of folic acid designed to efficiently coordinate with 99mTc for in vivo imaging by predominantly accumulating in folate receptor (FOLr)-positive tumors. Folate receptors, primarily folate receptor alpha or FOLr1 (FOLr) that participate in the internalization of folates into cells are overexpressed in a wide range of cases of primary and metastatic ovarian, lung, breast, endometrial, kidney and brain cancer.

Over the years several projects have been undertaken to conjugate FOLr with a cytotoxic payload including the antibody-drug conjugate IMGN853 currently in early clinical development. Another MAb-based drug in clinical development is farletuzumab (MORAb-003) that blocks FOLr. Also, immunotherapies based on FOLr in clinical development include FBP-E39 (GALE-301), and TPIV200. (more...

Ramucirumab Headed for FDA Approval in Gastric Cancer
Eli Lilly has completed submissions to USA and EU regulators for approval of for ramucirumab as monotherapy in patients with advanced gastric cancer in the second line setting based on results from the multicenter (n=161), international, randomized phase III clinical trial (protocol ID: 13893; 2008-005964-15; CP12-0715; I4T-IE-JVBD; NCT00917384), dubbed REGARD, with ramucirumab monotherapy (Fuchs CS, etal, ASCOGI13, Abs. LBA5). In addition, based on results from the RAINBOW phase III clinical trial, median OS in patients with metastatic gastroesophageal junction (GEJ) or gastric adenocarcinoma treated with ramucirumab plus paclitaxel in the second line setting was 2 months longer than in those treated with paclitaxel alone. The survival gain is considered significant in this difficult to treat disease. Results of the RAINBOW trial, combined with findings from the REGARD trial support the use of this drug as second line therapy in patients with advanced gastric cancer who can tolerate these regimens. In these two trials in the second line setting, ramucirumab was effective as monotherapy and in a combination regimen.

In February 2014, Eli Lilly also reported that in the REVEL global phase III clinical trial (protocol ID: 13852; I4T-MC-JVBA; 2010-021297-11; CP12-1027; NCT01168973), ramucirumab in combination with docetaxel in patients with non-small cell lung cancer (nsclc), in the second line setting statistically significantly improved OS, the trial's the primary endpoint compared to the control arm of placebo plus docetaxel. There was also a statistically significant improvement in PFS in the ramucirumab arm compared to the control arm. The company did not report further details. Ramucirumab is currently being evaluated in ongoing clinical trials in colorectal, liver and bladder cancer and non-squamous nsclc. Ramucirumab (IMC-1121B), an antiangiogenesis agent, is a human monoclonal antibody (MAb) that blocks the vascular endothelial growth factor receptor 2 (VEGFr2). (more...

Speeding the Time it Takes to Evaluate Novel Anticancer Treatments: the I-SPY-2 Adaptive Clinical Trial
Clinical evaluation of novel anticancer agents/treatments routinely takes over 10 years and costs nearly $1 billion.  Currently, numerous agents are in development for even longer lengths of time.  This situation prompted the rethinking of how to evaluate the results of clinical trials in real time rather than wait until the trial’s conclusion.  In this approach, referred to as adoptive design, the effectiveness of a treatment addressing a narrow clinical indication selected on validated science, is evaluated in a small patient population in real time using statistical techniques (Barker AD, etal, Clin Pharmacol Ther, Jul 2009;86(1):97-100) based on a Bayesian model to identify regimens with ≥85% predictive probability of success.  In this manner, a decision can be quickly arrived at as to the treatment’s effectiveness.  The first attempt to employ this approach is represented by the I-SPY 2 TRIAL (Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular analysis 2), a phase II clinical trial (protocol ID: 097517; NCT01042379) in women with newly diagnosed locally advanced breast cancer to test whether adding investigational drugs to standard chemotherapy is better than standard chemotherapy alone in the neoadjuvant setting (http://www.ispy2.org).  In this trial, various agents are used to treat a small number of patients with several types of breast cancer in the adjuvant setting to determine which are most effective in which patient based on disease characteristics and biomarker expression.  The trial’s primary endpoint is pathologic complete response (pCR).  The trial employs a rigorous patient profile based on the biology of each participant’s tumor and the outcome of each participant who completes treatment is used to decide treatment for women who subsequently join the trial.  Drugs that provide a benefit are then entered into late stage evaluation. (more...

The Incredible Complexity of Drug Development and Personalized Medicine in Oncology-Triple Negative Breast Cancer (TNBC)
Triple negative breast cancer (TNBC) is only one of the hundreds of distinct types of cancer.  It accounts for about 15% to 25% of all cases of breast cancer.  TNBC, characterized by a lack of expression of the hormone receptors for estrogen and progesterone and HEr2, is an aggressive form of breast cancer with no effective treatment options.  The severity of the disease and the commercial opportunity for an effective treatment that rivals the $1.5 billion market for Herceptin in triple positive breast cancer, has intensified research in this area.  Most novel agents in TNBC are in early clinical development with no standouts having emerged to date. (more...)

Inhibition of the Vascular Endothelial Growth Factor (VEGF) Pathway for the Treatment of Cancer

The success of Avastin, an antiangiogenesis agent targeting the VEGF pathway, has prompted the development of numerous similarly acting agents. Avastin, with global revenues of $6,210.5 million in fiscal 2010, is the most commercially successful anticancer drug ever to reach the market. Future Oncology has published a review of VEGF inhibition in the treatment of cancer. (more...)

Subscribers to New Medicine's Oncology KnowledgeBASE (nm|OK), log in to access the version providing active links to nm|OK records.







Home   |    Freelance Opportunities   |   New Medicine   |   Site Map   |  Order/Inquiry   

P.O. BOX 909, LAKE FOREST, CA 92609
PHONE:  1-949-830-0448     FAX:  1-949-830-0887